This application claims the benefit of U.S. Provisional Application Ser. No. 60/181,485 filed on Feb.10, 2000.
This work was supported at least in part by a grant award from the National Institutes of Health. The government may have certain rights to this invention.
Entry |
---|
Volpert et al. (J.Clin.Invest., 1996, vol. 98, No. 3 pp. 671-679).* |
Kim et al., (Drug Chem. Toxicol., 1989,vol. 12(3-4),abstract).* |
Hojo et al. (Nature, Feb. 11, 1999, vol. 397, pp. 530-534).* |
Wolf et al. (J.Clin.Invest, vol 92, 1993, pp. 1366-1372).* |
Paine-Murrieta et al. (Cancer Chemother.Pharmacol, vol. 40, 1997, pp. 209-214).* |
Baselga et al. (J.Natl.Canc.Inst., 1993, vol. 85, No. 16, abstract).* |
Tschmelitsch et al. (Canc.Res., 1997, vol. 57, No. 11,abstract).* |
M. Maluccio, et al., “Angiotensin II Receptor Blockade: A Novel Strategy to Prevent Immunosuppressant-Associated Cancer Progression”, Transplantation Proceedings (2001) 33 1820-1821. |
Hojo, et al., “Cyclosporine induces cancer progression by a cell-autonomous mechanism”, Nature (1999) 397 530-534. |
Gary J. Nabel, “A transformed view of cyclosporine”, Nature (1999) 397 471-472. |
Khanna, et al., “Regulation of new DNA Synthesis in Mammalian Cells by Cyclosporine”, Transplantation (1994) 57 577-582. |
Number | Date | Country | |
---|---|---|---|
60/181485 | Feb 2000 | US |